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Abstract
Introduction: Reliable rapid testing for COVID-19 is needed in care homes to reduce the risk of outbreaks and enable timely
care. This study aimed to examine the usability and test performance of a point of care polymerase chain reaction (PCR) test
for detection of SARS-CoV-2 (POCKITTM Central) in care homes.
Methods: POCKITTM Central was evaluated in a purposeful sample of four UK care homes. Test agreement with laboratory
real-time PCR and usability and used errors were assessed.
Results: No significant usability-related hazards emerged, and the sources of error identified were found to be amendable with
minor changes in training or test workflow. POCKITTM Central has acceptable sensitivity and specificity based on RT-PCR
as the reference standard, especially for symptomatic cases. Asymptomatic specimens showed 83.3% (95% confidence interval
(CI): 35.9–99.6%) positive agreement and 98.7% negative agreement (95% CI: 96.2–99.7%), with overall prevalence and
bias-adjusted kappa (PABAK) of 0.965 (95% CI: 0.932– 0.999). Symptomatic specimens showed 100% (95% CI: 2.5–100%)






/ageing/article/50/5/1464/6244503 by guest on 29 O
ctober 2021
The evaluation of rapid PCR for SARS-CoV-2 in care homes
provided to mitigate the frequency of occurrence of the residual use errors observed. Integration pathways were discussed to
identify opportunities and limitations of adopting POCKIT™ Central for screening and diagnostic testing purposes.
Conclusions: Point-of-care PCR testing in care homes can be considered with appropriate preparatory steps and safeguards.
Further diagnostic accuracy evaluations and in-service evaluation studies should be conducted, if the test is to be implemented
more widely, to build greater certainty on this initial exploratory analysis.
Keywords: care homes, COVID-19, older people, point-of-care-testing, polymerase chain reaction (PCR)
Key Points
• Point of care tests in care homes are feasible and could increase testing capacity for the control of COVID-19.
• The test of agreement between POCKIT™ Central and laboratory polymerase chain reaction for care home residents and
the staff was good.
• Adoption of POCKIT™ Central in care homes can be considered with appropriate preparatory steps and safeguards in place.
• Repetitive errors and test malfunctioning can be mitigated with bespoke training for care home staff.
• Pathways of adoption should be investigated to appreciate the high variability of the context of use.
Introduction
Care home residents have been amongst the worst affected
by the COVID-19 pandemic [1]. In England and Wales,
the Office of National Statistics estimates that care homes
experienced 21,344 excess deaths due to COVID-19 during
the first 10 months of the pandemic [2].
As the pandemic has continued, attention has turned to
how SARS-CoV-2 testing might help better protect residents
from COVID-19 outbreaks, whilst enabling continuity of
service provision and promoting quality of life for residents,
by restoring routine practices such as family visiting [3].
Point-of-care testing (POCT) describes tests that take
place close to the care setting [4, 5]. We have previously
described possible roles for POCT for COVID-19 in screen-
ing asymptomatic residents and staff, and diagnostic test-
ing for symptomatic residents and staff [6] For both use
cases, POCT could reduce administrative burden and test
turnaround times, and reduce the chances of COVID-19
outbreaks through earlier quarantine of positive cases.
The ‘real world’ effectiveness of POCT in care homes is
a function of the technical properties of the test (established
in laboratory conditions where certainty and parameters are
controlled) and its performance in the conditions of uncer-
tainty that exist in homes, such as residents with complex
multimorbidity, variation in testing behaviours in staff, vari-
able infection control processes and implementation. POCT
should take account of how testing can integrate into exist-
ing measures of transmission control, and the complexity
involved in preparing for testing, conducting testing, and
interpreting and responding to results.
Very little is known as to how well the POCTs can
be integrated into care home settings and their readiness
for adoption amongst potential users. If these POCTs are
implemented into settings that they have not been designed
for there is an inherent risk that the operator will execute the
test improperly, use it in the way not intended, or even reject
the test for lack of perceived benefits.
As part of the CONDOR platform [7], our study aim
was to evaluate a point-of-care polymerase chain reaction
(PCR) test for detection of SARS-CoV-2 in the UK care
home setting. Our primary objective was to rapidly explore
the usability and readiness of the technology for use in real-
world settings, scope usability requirements, prioritise areas
of deployment and identify any possible safety concerns and
sources of error to be further investigated and mitigated.
A secondary objective was to evaluate the agreement between
results from the POC test with the laboratory-based Reverse
Transcriptase-PCR (RT-PCR), the current benchmark stan-
dard for care homes.
Methods
The technology being evaluated was the POCKIT™ Central
Nucleic Acid Analyzer (POCKIT™ Central). This is a bench-
top molecular detection system, integrating magnetic bead-
based nucleic acid extraction, fluorescence-based insulated
isothermal PCR amplification/detection, and liquid han-
dling technologies to offer a walk-away protocol for nucleic
acid detection. The machine can run tests on up to eight
specimens at once. Results are displayed on the monitor
in less than 1.5 hours. POCKIT™ Central machines were
delivered directly to care homes, and training provided, by
the manufacturer. Only staff members who received formal
training were permitted to use the machine.
This study consists of two activities: (i) scoping usability
and use errors and (ii) test agreement with laboratory RT-
PCR.
No formal power calculation was undertaken. Further
evaluation of diagnostic accuracy is being conducted in other
parts of the CONDOR platform.
Participant recruitment
The CONDOR study has recruited 28 care homes, caring
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Table 1. Description of care homes and participants taking part in the study
Interviewee’s role Area Nursing home Residential home Total number of beds Identification code
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Care home manager Nottinghamshire X 80+ CH1
Managing director Nottinghamshire X 140+ CH2
Project improvement officer CH3
Chief nursing officer Oxfordshire X X 350+ CH4
Managing director Nottinghamshire X 50+ CH5
were recruited through publicity in a national care home
WhatsApp COVID-19 peer support group [8], public-
facing social media and the national care home umbrella
organisations Care England and the National Care Forum.
The care home database is active, and we continue to recruit.
It includes nursing and residential homes; corporate chain,
independent and third-sector providers; and bed capacity
ranging from 20+ to 350+ in each home. From this, we
selected a purposive sample of four care homes (Table 1),
comprising two care homes with nursing and two care homes
without nursing (also known as nursing and residential
homes respectively), from two regions of the UK, two
independents and two small chains, to ensure we maximised
our ability to account for differences in staff training, and
organisational configuration, that might impact on the
implementation or use of a POCT.
We chose the number of participants based upon
the need to understand workflows around staff and
resident routine testing, whilst capturing errors that
might occur on repeated use of the machine, by dif-
ferent staff members, on different days, under different
circumstances.
Scoping usability and use errors
To scope usability areas and potential sources of error, semi-
structured interviews were conducted with key stakeholders
(Table 1). These interviews also enabled further insights
regarding potential operational and pathway integration of
the new test. Participants were directly involved with trialling
POCKIT™ Central in care homes and had experience in
using the device.
Stakeholders were interviewed individually and remotely
by a researcher in human factors (MM) at the end of
the trial. In one instance, for reasons of practicality,
two interviewees who worked together were interviewed
together. Interviews were semi-structured and lasted 30–
60 minutes; they were audio and video recorded, with
the permission of the participants. Interview schedules
focused on the manufacturer’s instructions for use, how
POCKIT™ Central might be integrated into the diag-
nostic pathway, the testing strategy and the clinical
decision-making based on positive and negative results.
Participants were then prompted to explore potential
usability issues in the use of POCKIT™ Central (including
clarity of test results, potential hazards and the disposal
procedure).
Test agreement with laboratory PCR
We chose to focus primarily on routine staff testing. This
is currently conducted weekly, and results from PCR
laboratory tests do not always arrive within 7 days. A
growing body of evidence suggests that asymptomatic
transmission from staff is likely to be one of the most
important factors in care home outbreaks [9]. We estimated
that conducting 65 tests in each of the four care homes
would allow enough repetition of the testing procedure
to capture variability in practice between people and
over time. The breakdown of tests between the different
groups was 35 routine staff tests, 15 routine resident
tests, and 15 tests for resident or staff who had become
symptomatic.
Nasopharyngeal swabs were taken by care home staff,
adhering to standard testing procedures recommended
by the government [10], using government-issued testing
kits. Use of the POCKIT™ Central device followed a
Standard Operating Procedure (see Appendix I) written
by laboratory staff after risk assessing the extent of viral
inactivation in the sample buffer. Once the testing swab
had been inserted into the viral transport medium, 200 μl
was transferred into the POCKIT™ Central testing well by
the care home staff member using a pre-set Gilson pipette
and sterile filter tips. The remainder of the specimen was
sent for formal laboratory testing as usual. Care home staff
documented testing results from the POCKIT™ Central
device using a results log, adding formal laboratory results
when these returned. Only anonymised data were seen
by the research team. Samples were not blinded at any
stage.
All test results, including equivocal results and failures,
were reported as per US Food and Drug Administration
guidance [11]. We calculated positive and negative agree-
ment of POCKIT™ Central with the formal laboratory
RT-PCR results, the (Cohen) kappa, the Brennan and Predi-
ger statistic (equal to the prevalence and biassed adjusted
kappa (PABAK)) as well as prevalence based on labora-
tory RT-PCR results, with their associated 95% confidence
intervals (CI). The primary analysis was based on valid
results for all tests stratified by symptomatic/asymptomatic
participants. These calculations were carried out in Stata/SE
16.1 using: diagt and kappaetc. We also carried out a sen-
sitivity analysis including all POCKIT™ Central equivo-








/ageing/article/50/5/1464/6244503 by guest on 29 O
ctober 2021
The evaluation of rapid PCR for SARS-CoV-2 in care homes
Figure 1. Flowchart of the operative procedure and potential risks errors of use associated, as highlighted by human factors experts.
Results
Scoping usability and use errors
The human factors experts reviewed all potential critical
issues in the main operation tasks of POCKIT™ Central that
could lead to errors and hazards affecting the test operators
and the care home residents. Instructions for use and a
video demonstration were analysed to highlight the expected
source of errors. Four operation tasks and potential risks of
use and errors were identified and are outlined in Figure 1.
Each task and the probability of occurrence of these potential
errors were discussed with interview participants.
The overall experience with testing equipment was pos-
itive. Using the device did not cause excessive cognitive
workload as users easily remembered the required steps.
Handling components and inserting them into the correct
location was not problematic and did not lead to errors.
The test activation—which included navigating the digital
interface—was considered ‘easy to manage’ (CH2–CH3)
and staff members appreciated the presence of prompts and
a home button for better control of the process (CH1). No
results misinterpretation was observed. Results were correctly
recorded. Each test was linked to a unique ID and the data
automatically saved for retrieval.
The list of observed errors and unexpected situations has
been divided based on the four operative procedure’s stages.
Relevant quotes from participants and mitigation strategies
to reduce the occurrence of errors are reported (Table 2).
Quotes are selected for their relevance to inform key usability
aspects and to corroborate findings.
Integration pathway
Further comments covered the integration aspect of POCT
in a care home setting. To run tests correctly, to safeguard
operators and residents, and to protect the testing equip-
ment from damage, a dedicated room must be set up with
operators wearing fresh PPE. As CH4 explained: ‘I do think
we need a dedicated room, which remains a dedicated room
for long. It is because it’s a heavy machine. And you would
not be transporting it from place to place (risk of damages)
[ . . . ] Dedicated room (that serves all the different houses)
made into the testing room, separate from homes, outside
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Table 2. List of observed errors of use and mitigation strategies
Potential use errors Frequency of
occurrence
Description and direct quotes from
participants
Mitigation strategies
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Task 1—Cartridge setup No standard materials used 0 cases
Damaged equipment 1 case ‘the various elements of the cartridge
had come loose, and the lid had
come off’ (CH2-CH3).
Leaflet for a rapid check of
package content with visual
Misplaced cartridges 0 cases ‘It can only fit the right [location] at
the right time. So, if you have
picked up the wrong cartridge at
that point when it prompted you
to put it in, it wouldn’t fit’ (CH1)
One-way interlocking components
User forgets the correct
sequence of steps
0 cases
Reagents not stored properly 1 case ‘Reagents are expected to be stored
in a fridge and this was not
explained clearly during the
training’ (CH2-CH3).
Support for operators:
implementation of training and
Instruction for use (e.g.
dedicated video demonstration
regarding frequent errors and
malfunctions)
Task 2—insert the cartridge
and initiate test
Foil lid not removed as
indicated
2 cases The aluminium foil did not remove
one of the glue coverings: a small
amount of glue and foil was left on
the cassette. The prong got caught
and it tipped it over slightly and
took the casing off the prong
(CH4).
Unclear aluminium foil removal
procedure – ‘One batch was
processed without the foil being
pulled back, but it seems to
produce unchanged results. So, I’m
not quite sure . . . And results were
reported without the machine
going into failure mode’ (CH4).
Design changes I: dye-coloured
glue coverings to make residual
visible;
Design changes II: peeling-off
symbol depicted on the
aluminium foil surface;
Procedure changes: Internal
quality control from operators
(e.g. cartridge surface cleaning
with dedicated wipe).
Premix container not locked
into place
0 cases









Labels not visible 0 cases
User forgets sequence of steps 1 case Sample run twice: no warning
message – ‘With the second batch
[of tests], I ran into a problem. I
put a sample from the same tube
into the process, so where only
seven samples, one of them was
duplicated. As soon as I moved on
to the next sample, I realised it was
a mistake’ (CH4)
The user inserts incorrect
extraction lot number and
reagent lot number
0 cases
User not able to troubleshoot 1 case Malfunctioning door closing - ‘We
had a problem with the door
closure of the equipment, which





implementation of training and
Instruction for use (e.g.
dedicated video demonstration
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Table 2. Continued
Potential use errors Frequency of
occurrence
Description and direct quotes from
participants
Mitigation strategies
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interface not prompting
correctly
1 case Faulty message: the ‘remove the
cartridge’ message appeared on
screen although cartridges were
correctly removed from the machine.
Staff members reported splash marks
and one stated ‘small splash marks
on the cartridge holder which I
gently wiped away with an
antibacterial wipe. This worked and
cleared the message and the machine
continued to close the door and
move on’ (CH2–CH3).
The manufacturer was called, and he
advised not to use alcohol-based
wipes for this in future but that the
response had otherwise been correct.
The company did not foresee any
risk of spillage.
Support for operators:
implementation of training and
Instruction for use (e.g. dedicated
video demonstration regarding
frequent errors and malfunctions)
Interface (touch screen) not
responsive
0 cases





1 case The same sample runs twice on
POCKIT™ Central: a positive result
first and a negative result
subsequently were shown (CH2).





results failed to be exported
on a USB drive
0 cases
Task 4—dispose of the
material
0 cases
Two ways in which the test results might inform practice
were discussed: (i) the diagnostic test for symptomatic resi-
dents and staff and (ii) the screening test for asymptomatic
residents and staff.
As a one-off test, POCKIT™ Central was considered by
staff to be appropriate for testing symptomatic residents and
for obtaining a rapid result to enable timely care decisions:
‘I can see a huge advantage because for those people that
are symptomatic suddenly; I think it could solve a lot of
situations for which you see an immediate answer, or a more
immediate answer would be useful to complement it on it’
(CH1).
A rapid test would better inform isolation decisions,
avoiding unnecessary segregation, with benefits to residents’
wellbeing and the wider care home community: ‘when we’ve
had people who were symptomatic, rather than having to
close the community we would now put in all the precau-
tions without stopping relatives coming in [ . . . ] we only
have to have two suspected or two confirmed cases’ (CH4).
This technology would contribute to maintaining a testing
momentum in care home facilities, and it would provide a
consistent diagnostic approach. Having care home managers
in control would relieve the burden of managing unpre-
dictable factors, including frequent changes of government
strategy around testing and isolation: ‘And this would allow
us to test people and keep the workforce in a constant
continuity for the people in our care. It offers reassurance
to the staff’ (CH4).
However, the main concern of staff was the test
turnaround of 85 minutes, as they considered it would
require extra staff capacity to test the whole home in
approximately 2 days. Given the test turnaround time, we
identified considerable staffing issues with asymptomatic
cases, as these will require significant amounts of staff time:
‘If you’re wanting to replace testing here with something
like that, the capacity of it in the time it would take to get
through the number of people we need to get to. Which
would be a huge problem here’ (CH1).
In big care homes (200+), it might take more than 2
days to screen all the residents if POCTs were deployed
in this context. The staff in all care homes outnumbered
the residents, and are currently subject to weekly testing,
implying even greater workload. Consideration should be
given to the resource implications for care homes. There
was some disagreement amongst respondents about whether
this would essentially mirror the staffing requirements for
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Figure 2. STARD flow diagram.




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
POCKIT Negative Positive Uncertain/error Total
Negative 222 1 4 227
Positive 3 5 0 8
Uncertain/error 17 0 0 17
Total 242 6 4 252
Symptomatic cases
Laboratory (PCR)
POCKIT Negative Positive Uncertain/error Total
Negative 24 0 1 25
Positive 0 1 0 1
Uncertain/error 0 0 0 0
Total 24 1 1 26
Agreement with laboratory RT-PCR
In total, 278 tests were run. Tests were conducted on 252
asymptomatic participants (176 staff and 76 residents) and
26 symptomatic participants (13 staff and 13 residents)
(Table 3 and Appendix II Table A1 stratified by staff/res-
idents). Formal laboratory results were indeterminate for
five specimens. POCKIT™ Central results were not available
for 17 tests: 1 was a sporadic error, and the remaining
16 were compromised by sealing glue left on top of the
POCKIT™ Central cartridge. This was an avoidable error,
which is described in detail above. A standard for reporting of
diagnostic accuracy studies (STARD) Flow diagram is shown
in Figure 2.
Thus, agreement analysis was conducted on 256 spec-
imens: 177 from staff, 164 asymptomatic and 13 symp-
tomatic; 79 from residents, 67 asymptomatic and 12 symp-
tomatic. Estimated prevalence data, positive and negative
agreement, and kappa and PABAK results for asymptomatic
and symptomatic participants are shown in Table 4. Equiv-
alent statistics based on including all POCKIT™ Central
equivocal and failures are reported in Appendix II Table A2.
Table 4. Agreement based on valid measuresa
Asymptomatic cases
LAB −ve LAB +ve Total
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
POCKIT negative 222 1 223
POCKIT positive 3 5 8
Total 225 6 231
Test attributes (95% CIs)










LAB −ve LAB +ve Total
POCKIT negative 24 0 24
POCKIT positive 0 1 1
Total 24 1 25
Test attributes (95% CIs)









aAll CIs are based on standard Stata commands: For Sensitivity, Specificity,
PPV and NPV (except with the prevalence option), exact binomial CIs are
given, (command ci). ROC area (Receiver Operating Characteristic) uses
roctab. LR+ and LR- (based on risk ratio) and odds ratio all use command cs.
Discussion
This paper reports the first exploratory in-context evaluation
of point-of-care (POC) PCR for SARS-CoV-2 in the care
home setting. We found no significant hazards and the
sources of error identified were amenable to relatively minor
changes in training or test workflow. Therefore, adopting
POCKIT™ Central in a care home setting can be considered
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The positive and negative agreement reported in this
study can be compared with the measures of sensitivity
and specificity based on RT-PCR as the reference standard.
The estimates presented here for POCKIT™ Central were
acceptable, particularly for symptomatic participants.
Overall, participants reacted enthusiastically to the possi-
bility of implementing their care home’s testing capability;
the ability to promptly react on results, especially if positive,
has a great effect on staff confidence and it might limit the
detrimental effects of unnecessary isolations of residents. As
part of the effort to gradually re-open care homes to planned
visits, a POC test will contribute to the opportunity to screen
care home visitors for COVID-19. However, the specific
workflow or safety issues associated with testing visitors
were not investigated in this study; given the atypicality
of virus presentation and still unclear relations between
viral load and shedding, infection and infectiousness [12],
results from POCT should be used in combination, and
not as a substitute for infection prevention measures. When
applying the study findings to the management of visitors
to care homes in England, it is important to take into
consideration that the rapid testing including POCKIT™
investigated in this study is not a panacea to prevent the
transmission of COVID-19 but one of the enablers to guide
isolation decisions for visitors, staff and patients in care
homes. Therefore, the integration of POCT in care homes
should not displace any of the existing infection control mea-
sures such as wearing masks, PPE, social distancing, test-trace
systems.
The technology, as expected for PCR, shows much higher
accuracy, based upon the level of positive agreement seen,
than the lateral flow devices recently deployed as part of
the UK mass testing programme [13]. PCR is likely to
be substantially more expensive in terms of up-front costs
than using lateral flow tests. It does, though, potentially
represent a single step testing solution, shifting expense from
laboratories to the community. This would offer signifi-
cant resource savings for care homes in comparison with
the multi-stage testing approaches that might be needed
if using currently available lateral flow tests. The wider
work of the CONDOR programme involves care pathway
mapping which is informing National Institute for Health
and Care Excellence exploratory economic modelling of
SARS-CoV-2 viral detection POCTs [14]. This will con-
sider the cost of novel POCTs as compared with standard
laboratory testing alongside the potential benefits accumu-
lated.
An important practical consideration before any rollout
of this technology is that the CE mark (Conformitè
Europëenne) for the POCKIT™ Central, by which the
Medicines and Healthcare Products Regulatory Agency
defines its terms of use, restricts its use to ‘healthcare
professionals’. Although some are registered nurses, many
care home staff are not registered healthcare professionals.
The CE mark would have to be modified to take this into
account. This is not likely to be confined to POCKIT™
Central and is a reflection of the fact that POC tests have
not hitherto been widely deployed in care homes. If such
technology is to be widely deployed, then CE marks will have
to take account of the competency mix of care home staff.
A key limitation of this study is that it was not statistically
powered to evaluate diagnostic accuracy. The low number of
positives seen explains the wide CIs reported for all estimates,
particularly positive agreement. We report several measures
of agreement stratified by symptomatic/asymptomatic to
reflect potential different use of these tests. These statistics
have been shown to have limitations and biases but can
serve as an indication of overall agreement between these
tests, hence our reporting of multiple measures alongside
full test results. Our sensitivity analysis to explore the impact
of POCKIT™ Central uncertain results and machine errors
showed our results to be robust.
Another limitation is the relatively small sample of
care homes involved. Although we sought to evaluate the
technology in a purposive sample of homes that represented
the range of training and registration across UK care homes
more generally, the organisational configuration of UK care
is recognised to be highly heterogeneous. Also, the ‘early
adopter’ care homes that routinely engage with research
or service development by academics might be atypical. If
wider rollout of POCKIT™ Central in care homes were to
be considered as a consequence of this evaluation, we would
recommend doing so in a staged way, with further in-service
evaluation studies to tailor training/training material for care
homes staff and to fully assess how POCKIT™ Central can
be integrated into the full range of care home workflows.
A robust statistically powered diagnostic accuracy study
conducted in parallel could provide conclusive evidence as
to whether POCKIT™ Central compared with laboratory
RT-PCR performs as well in the care home setting as it does
in other contexts.
In conclusion, this evaluation of POCKIT™ Central high-
lights that POCT PCR for COVID-19 settings is feasible in
care home settings. We have not, hitherto, identified signifi-
cant safety concerns. The agreement with diagnostic bench-
mark laboratory PCR tests was good. If implemented at
greater scale, further diagnostic accuracy evaluations along-
side a further evaluation of usability and integration should
be conducted in parallel. This could include evaluation of
additional use cases, including extending testing to care
home visitors.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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